Han Rongcheng (b. 1978), an associate professor at the Chinese Academy of Sciences’ Institute of Genetics and Developmental Biology, is a leading innovator in nanomedicine-driven cancer therapy. His interdisciplinary work merges nanobiology, AI, and materials science to advance precision oncology. Core Achievements: 1. Targeted Nanodrug Systems: Engineered multifunctional nanomaterials (quantum dots, gold nanoclusters, etc.) with optimized drug delivery, imaging, and therapeutic capabilities. Developed interstitial nanodrug carriers to enhance tumor-specific drug accumulation. 2. Hypoxia-Resistant Therapies: Pioneered Type I two-photon photodynamic therapy and radiodynamic therapy to overcome hypoxia in tumors, enabling deeper penetration and sustained efficacy. Created in situ nanovaccines to activate immune responses and inhibit metastasis. 3. Translational Biomaterials: Designed biocompatible hydrogels for rapid hemostasis/tissue repair and hybrid nanosystems for theranostics. Impact: Published 21 papers (9 Q1, 14 as lead/corresponding author) and secured 17 patents (8 granted) on nanodrug synthesis, tumor-targeted delivery, and smart therapy platforms. His innovations redefine nanomedicine in addressing drug delivery challenges, modulating tumor microenvironments, and enabling clinical translation.